Pfizer (NYSE:PFE) plans to invest $600M in biotechnology and other emerging growth companies through Pfizer Ventures. Pfizer Ventures will seek to invest ~25% of its available capital ($150M) in promising early-stage neuroscience companies.
Beyond neuroscience, Pfizer Ventures will continue to invest across a broad range of therapeutic areas of interest such as oncology, inflammation and immunology, rare disease, internal medicine and vaccines.
Shares are up a fraction premarket.
Now read: Your Dogs Of The Dow For June »
Subscribe for full text news in your inbox